Genmab — Januar 2023

[E_L]

yes it was. it isn't a surprise as they stopped recruiting in september. it isn't completely dead, the trial continues with existing patients but i don't think we should expect anything anymore on it.

[E_L]

then again, i don't think you did if i remember correctly

[E_L]

JNJ's pipeline priorities https://jnj-content-lab.brightspotcdn.com/18/f6/b12412444e76b6f9775371de1dd0/jnj-pipeline-4q2022.pdf

[Sukkeralf]

No I remember we talked about this asset before so thats was kind of expected

[E_L]

another small Teclistamab in Combination with Daratumumab trial https://clinicaltrials.gov/ct2/show/NCT05695508

[ProinvestorNEWS]

Regnskabssæsonen - kontant afregning ved kasse 1
Regnskabssæsonen er for alvor i gang. Goldman Sachs, Tesla, Topdanmark, Tryg og Netcompany er oppe at vende. Derudover kommer Helge Larsen ind på pharma-, biotek- og laksesektoren.

Kort video: https://www.proinvestor.com/boards/109855

[E_L]

EPCORE DLBCL-2
started recruiting earlier this month https://clinicaltrials.gov/ct2/show/NCT05578976

[E_L]

Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma https://ascopost.com/issues/january-25-2023/study-shows-activity-of-talquetamab-in-highly-refractory-multiple-myeloma/

[bikube]

Jeg lod mig narre af "EPCORE_DLBCL 2". Det er fase 3.

[E_L]

and EPCORE DLBCL-3 is phase 2, just to make it easy for you

[bikube]

HaHa.

[E_L]

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement https://pubmed.ncbi.nlm.nih.gov/36699620/ "We add to existing limited data that Daratumumab penetrates the blood-brain barrier."

[Solsen]

Det bliver interessante data med Carvykti https://www.businesswire.com/news/home/20230127005056/en/Legend-Biotech-Announces-Phase-3-CARTITUDE-4-Study-of-CARVYKTI-ciltacabtagene-autoleucel-Has-Met-Its-Primary-Endpoint-in-the-Treatment-of-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma

[E_L]

Medicinrådet afviser daratumumab til patienter med systemisk AL amyloidose https://haematologisktidsskrift.dk/sygdomme/1127-medicinradet-afviser-daratumumab-til-patienter-med-systemisk-al-amyloidose.html

[E_L]

Professor: Medicinrådets afgørelse er chokerende https://haematologisktidsskrift.dk/sygdomme/myeloma/1128-professor-medicinradets-afgorelse-er-chokerende.html

[Bulder]

Carvykti bliver nok først og fremmest en konkurrent til teclistamab. Samme pt-gruppe og samme taget. Men lad os nu se hvad dara+tec-kombien kan drive det til.

[Bulder]

Taget

[Bulder]

Target for pokker da. Dumme ipad.

[Bulder]

For patienterne er afvisningen kedelig. Men dara indgår jo også i dvmp.

[royal]

Tænker professoren er én af dem der kender Dara bedst.